• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA clears breast biopsy device

Article

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will allow physicians to perform immediate biopsies on suspicious breast masses during an Avera imaging session, according to the company.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.